Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tazemetostat + Pembrolizumab in Resistant HNSCC
NCT04624113Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tazemetostat in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Washington University School of Medicine. Primary endpoints: Recommended Phase 2 Dose at 9 months and Objective Response Rate at 5 months. Started Apr 2021; status: terminated.
02
Drugs
tazemetostat
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04624113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624113.